FDA Opens eCTD v4.0 Sample Submission Pathway to Reduce Technical Filing Errors

Regulatory affairs teams preparing first-time eCTD v4.0 submissions now have a structured pre-filing validation route through FDA, one that surfaces technical errors before they reach official review queues and trigger refuse-to-file actions. The agency's sample submission program accepts test packages for NDA, IND, BLA, ANDA, and MF holders who plan an actual submission within 12 months of the sample request.

The process runs in four discrete steps: securing a Sample Application Number via [email protected], submitting the test package through ESG NextGen as a Test Submission, resolving all flagged errors against FDA's eCTD v4.0 validation tool output, and consulting submission support resources where conformance gaps persist. Standardized study datasets, CDISC/SDTM, CDISC/ADaM, and CDISC/SEND, can be bundled into the same sample package, making this a single checkpoint for both structural and data-standard conformance.

For QA and regulatory operations leads, the scope boundary is worth noting: FDA's review is limited strictly to conformance against supported electronic submission and data standards. No scientific or content review occurs at any stage, and sample packages are never seen by FDA application reviewers. Any data anomalies that carry a legitimate scientific explanation must be documented in the study data reviewer's guide before the actual submission is filed, not flagged informally during the sample phase.

The email request to initiate a Sample Application Number must include the applicant's contact details, the relevant application number, the planned official submission date, and a description of the test type, whether eCTD v4.0 new application, eCTD v4.0 Forward Compatibility, or a specific CDISC dataset format. That same information should appear verbatim in the cover letter of the sample submission itself. Once a sample is submitted and results returned, resubmission of sample materials is not evaluated further; sponsors must move directly to correcting the identified issues in their actual filing.

Feedback is generally returned within 30 days of receipt, though FDA notes that turnaround may extend during periods of high submission volume, a scheduling variable that regulatory teams should factor into submission timelines, particularly around known filing clusters at fiscal year-end or following major guidance releases.

Teams that resolve all eCTD and data conformance issues identified in the sample feedback before filing will be positioned to avoid the technical rejection cycles that delay application clock starts under 21 CFR Part 314 and equivalent BLA pathways.

Source: FDA Drugs, What's New RSS Feed via fda.gov, 29 October 2026.